Concentration-dependent dual effect of thrombin on impaired growth/apoptosis or mitogenesis in tumor cells

Blood

Volumn 95, Issue 10, 2000, Pages 3133-3138

  Zain, Jasmine ^a   Huang, Yao Qi ^a   Feng, XueSheng ^a   Nierodzik, Mary Lynn ^a   Li, Jian Jun ^a   Karpatkin, Simon ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE INHIBITOR; LIPOCORTIN 5; THROMBIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME REGULATION; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; INHIBITION KINETICS; MITOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

EID: 0034658083     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.10.3133.010k31_3133_3138     Document Type: Article

References (45)

1. Nierodzik ML, Kajumo F, Karpatkin S. Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and metastasis in vivo. Cancer Res. 1992;52:3267-3272.
2. Nierodzik ML, Chen K, Takeshita K, et al. Protease-activated receptor 1 (PAR-1) is required and rate-limiting for thrombin-enhanced experimental pulmonary metastasis. Blood. 1998;92:3694-3700.
3. Grand RJA, Turnell AS, Grabham PW. Cellular consequences of thrombin-receptor activation. Biochem J. 1996;313:353-368.
4. Nierodzik ML, Plotkin A, Kajumo F, Karpatkin S. Thrombin stimulates adhesion of tumor cells to platelets: requirement of GPIIb/GPIIIa and an RGD-dependent mechanism. J Clin Invest. 1991; 87:229-236.
5. Klepfish A, Greco MA, Karpatkin S. Thrombin stimulates tumor cell binding to endothelial cells and subendothelial matrix. Int J Cancer. 1993;53: 978-982.
6. Pearlstein E, Ambrogio C, Karpatkin S. Effect of anti-platelet antibody on the development of pulmonary metastases following injection of CT26 colon adenocarcinoma, Lewis lung carcinoma and B16 amelanotic melanoma tumor cells in mice. Cancer Res. 1984;44:3884-3887.
7. Karpatkin S, Pearlstein E, Ambrogio C, Coller BS. Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. J Clin Invest. 1988;81:1012-1019.
8. Pearlstein E, Ambrogio C, Gasic G, Karpatkin S. Inhibition of platelet aggregating activity of two human adenocarcinoma of the colon and an anaplastic murine tumor with a specific thrombin inhibitor: dansylarginine N-(3-ethyl-1,5-pentanediyl)-amide. Cancer Res. 1981;41:4535-4539.
9. Sarin A, Wu M-L, Henkart PA. Different interleukin-1b converting enzyme (ICE) family protease requirements for the aoptotic death of T lymphocytes triggered by diverse stimuli. J Exp Med. 1996;184:2445-2450.
10. Cheng Y, Deshmukh M, D'Costa A, et al. Caspase inhibitor affords neuroprotection with delayed administration in a rat model of neonatal hypotic ischemic brain injury. J Clin Invest. 1998; 101:1992-1999.
11. Vistica DT, Skehan P, Scudiero D, Monks A, Pittman A, Boyd MR. Tetrazolium-based assays for cellular viability: a critical examination of selected parameters affecting formazan production. Cancer Res. 1991;51:2515-2520.
12. Xu WF, Andersen H, Whitmore TE, et al. Cloning and characterization of human protease-activated receptor 4. Proc Natl Acad Sci U S A. 1998;95: 6642-6646.
13. Kahn ML, Hammes SR, Botka C, Coughlin SR. Gene and locus structure and chromosomal localization of the protease-activated receptor gene family. J Biol Chem. 1998;272:23,290-23,296.
14. Goldfarb M, Deed R, MacAllan D, Walther W, Dickson C, Peters G. Cell transformation by Int-2, a member of the fibroblast growth factor family. Oncogene. 1991;6:65-71.
15. Nanevicz T, Wang L, Chen M, Ishii M, Coughlin SR. Thrombin receptor activation mutations: alteration of an extracellular agonist recognition domain causes constitutive signalling. J Biol Chem. 1996;271:702-706.
16. Vouret-Craviari V, Van Obberghen-Schilling E, Rasmussen UB, Pavirani A, Lecocq JP, Pouyssegur J. Synthetic alpha-thrombin receptor peptides activate G protein-coupled signalling pathways but are unable to induce mitogenesis. Mol Biol Cell. 1992;3:95-102.
17. Vouret-Craviari V, Van Obberghen-Schilling E, Scimeca JC, Van Obberghen E, Pouyssegur J. Differential activation of p44 mapk (ERK1) by alpha-thrombin and thrombin receptor peptide agonist. Biochem J. 1993;289:209-214.
18. Strasser-Wozak EM, Hartmann BL, Geley S, et al. Irradiation induces G2/M cell cycle arrest and apoptosis in p53-deficient lymphoblastic leukemia cells without affecting Bcl-2 and Bax expression. Cell Death Differ. 1998;5:687-693.
19. Tashiro E, Dimizu S, Takada M, Umezawa K, Imoto M. Caspase-3 activation is not responsible for vinblastine-induced BCL-2 phosphorylation and G2/M arrest in human small cell lung carcinoma MS-2 cells. Jpn J Cancer Res. 1998;89: 940-946.
20. Vu T-KH, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 1991;64:1057-1068.
21. + mobilization. FEBS Lett. 1991;288:123-128.
22. Nierodzik ML, Bain MR, Liu L-X, Shivji M, Takeshita K, Karpatkin S. Presence of the seven transmembrane thrombin receptor on human tumor cells: effect of activation on tumor adhesion to platelets and tumor tyrosine phosphorylation. Br J Haematol. 1996;92:452-457.
23. Wojtukiewicz MZ, Tang DG, Ciarelli JJ, et al. Thrombin increases the metastatic potential of tumor cells. Int J Cancer. 1993;54:793-806.
24. Wojtukiewicz MZ, Tang DG, Ben-Josef E, Renaud C, Walz DA, Honn KV. Solid tumor cells express functional tethered ligand thrombin receptor. Cancer Res. 1995;55:698-704.
25. Chen LB, Buchanan JM. Mitogenic activity of blood components. I: thrombin and prothrombin. Proc Natl Acad Sci U S A. 1975;72:131-135.
26. Carney DH, Glenn KC, Cunningham DD. Conditions which affect initiation of animal cell division by trypsin and thrombin. J Cell Physiol. 1978;95: 13-22.
27. Glenn KC, Carney DH, Fenton JW, Cunningham DD. Thrombin active site regions required for fibroblast receptor binding and initiation of cell division. J Biol Chem. 1980;255:6609-6616.
28. Carney DH, Stiernberg J, Fenton JW. Initiation of proliferative events by human a-thrombin requires both receptor binding and enzymic activity. J Cell Biochem. 1984;26:181-195.
29. Morris DL, Ward JB Jr, Carney DH. Thrombin promotes cell transformation in Balb 3T3/A 31-1-13 cells. Carcinogenesis. 1992;13:67-73.
30. McNamara CA, Sarembok IJ, Gimple LW. Thrombin stimulation of smooth muscle cell proliferation is mediated by a proteolytic, receptor-mediated mechanism. J Clin Invest. 1992;91:94-98.
31. Brass L. Homologous densitization of HEL cell thrombin receptors: distinguishable roles for proteolysis and phosphorylation. J Biol Chem. 1992; 267:6044-6050.
32. Huang Y-Q, Li J-J, Karpatkin S. Thrombin inhibits tumor cell growth in association with upregulation of p21 and caspases via a p53-independent STAT-1 dependent pathway. J Biol Chem. 2000; 275:6462-6468.
33. Honn KV, Sloane BF, Cavanaugh PG. Role of the coagulation system in tumor-cell-induced platelet aggregation and metastasis. Haemostasis. 1988; 18:37-46.
34. Fisher EG, Ruf W, Mueller BM. Tissue factor-initiated thrombin generation activates the signaling thrombin receptor on malignant melanoma cells. Cancer Res. 1995;55:1629-1632.
35. Mueller BM, Reisfeld RA, Edgington TS, Ruf W. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci U S A. 1992;89:11,832-11,836.
36. Bromberg ME, Konigsberg WH, Madison JF, Pacoashe A, Garen A. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci U S A. 1995;92:8205-8209.
37. Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nature Med. 1996;2: 209-215.
38. Rickles F, Shoji M, Abe K, et al. Hyperexpression of tissue factor in human tumor cells results in high vascular endothelial growth factor (VEGF) production in vitro and increased vascular permeability in vivo. Thromb Haemostas. 1997;77 suppl:OC-800.
39. Zhang Y, Deng Y, Luther T, et al. Tissue factor controls the balance of angiogenic and autoangiogenic properties of tumor cells in mice. J Clin Invest. 1994;94:1320-1327.
40. Zacharski LR, Memoli VA, Morain WD, Schlaeppi J-M, Rousseau SM. Cellular localization of enzymatically-active thrombin in intact tissue by hirudin binding. Thromb Haemostas. 1995;73: 793-797.
41. Even-Ram S, Uziely B, Cohen P, et al. Thrombin receptor overexpression in malignant and physiological invasion processes. Nature Med. 1998;4: 909-914.
42. Merskey C, Johnson AJ, Harris JU, Want MT, Swain S. Isolation of fibrinogen-fibrin related antigen from human plasma by immune-affinity chromatography: its characterization in normal subjects and in defibrinating patients with abruptio placentae and disseminated cancer. Br J Haematol. 1980;44:655-670.
43. Peuscher FW, Cleton FJ, Armstrong L, Stoepman van Dalen EA, van Aken WG. Significance of plasma fibrinopeptide A (FPA) in patients with malignancy. J Lab Clin Med. 1980;96:5-14.
44. Yoda Y, Abe T. Fibrinopeptide A (FPA) level and fibrinogen kinetics in patients with malignant disease. Thromb Haemostas. 1981;46:706-709.
45. Rickles FR, Edwards RC, Barb C, Cronlund M. Abnormalities of blood coagulation in patients with cancer: fibrinopeptide A generation and tumor growth. Cancer. 1983;51:301-307.